Glancy Prongay & Murray LLP (GPM) announces an investigation on behalf of Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY) investors concerning the Company and its officers possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
The investigation concerns whether the Company overstated the efficacy and safety of Alnylams lipid complex injection ONPATTRO. And, the Companys shares fell following news that a FDA review document highlighted specific risks associated with ONPATTRO following the cardiac deaths in patients treated with ONPATTRO.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased Alnylam, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.